Prospects for a globally effective HIV-1 vaccine.
Bethesda, United States. In Vaccine, Jul 2015
A correlates analysis compared vaccine-induced immune responses in vaccinated-infected and vaccinated-uninfected volunteers suggested that IgG specific for the V1V2 region of gp120 was associated with reduced risk of HIV-1 infection and that plasma Env IgA was directly correlated with infection risk.
Aptamer-siRNA chimeras for HIV.
Duarte, United States. In Adv Exp Med Biol, Dec 2014
So far, aptamers against either HIV-1 gp120 or CD4 have been eagerly evaluated as the aptamer portion of the aptamer-siRNA chimeras for the treatment or prevention of HIV-1.
Maraviroc: a review of its use in HIV infection and beyond.
Omaha, United States. In Drug Des Devel Ther, Dec 2014
The human immunodeficiency virus-1 (HIV-1) enters target cells by binding its envelope glycoprotein gp120 to the CD4 receptor and/or coreceptors such as C-C chemokine receptor type 5 (CCR5; R5) and C-X-C chemokine receptor type 4 (CXCR4; X4), and R5-tropic viruses predominate during the early stages of infection.